학술논문
The ICS/Formoterol Reliever Therapy Regimen in Asthma: A Review.
Document Type
Academic Journal
Author
Beasley R; Medical Research Institute of New Zealand, Wellington, New Zealand; Capital and Coast District Health Board, Wellington, New Zealand; Victoria University of Wellington, Wellington, New Zealand. Electronic address: Richard.Beasley@mrinz.ac.nz.; Bruce P; Medical Research Institute of New Zealand, Wellington, New Zealand.; Houghton C; Medical Research Institute of New Zealand, Wellington, New Zealand.; Hatter L; Medical Research Institute of New Zealand, Wellington, New Zealand; Victoria University of Wellington, Wellington, New Zealand.
Source
Publisher: Elsevier Inc Country of Publication: United States NLM ID: 101597220 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 2213-2201 (Electronic) NLM ISO Abbreviation: J Allergy Clin Immunol Pract Subsets: MEDLINE
Subject
Language
English
Abstract
The Global Initiative for Asthma recommends that low-dose inhaled corticosteroid (ICS)/formoterol be preferred to short-acting beta 2 -agonists as reliever therapy in adolescents and adults with asthma, across the range of asthma severity. This recommendation represents the most fundamental change in asthma management for many decades. In this commentary, we review the rationale for combination ICS/formoterol therapy, the evidence on which this recommendation has been made, the limitations in the evidence, the practical issues relevant to the implementation of ICS/formoterol reliever-based regimens in clinical practice, and the emerging evidence for the efficacy and safety of combination ICS/salbutamol reliever therapy regimens.
(Copyright © 2023 The Authors. Published by Elsevier Inc. All rights reserved.)
(Copyright © 2023 The Authors. Published by Elsevier Inc. All rights reserved.)